Heron Therapeutics (HRTX) EBT (2010 - 2026)

Heron Therapeutics (HRTX) has reported EBT for 17 consecutive years, with -$2.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBT fell 24.71% year-over-year to -$2.0 million; the trailing twelve-month figure through Jun 2026 stood at -$8.9 million (down 286.09% YoY), and the FY2025 full-year result was -$10.2 million, up 27.23% from the prior year.
• EBT grew to -$2.0 million in Q2 2026 per HRTX's latest filing, from -$4.8 million in the prior quarter.
• Across five years, EBT topped out at $7.7 million in Q4 2024 and bottomed at -$62.9 million in Q1 2022.
• Historically, EBT has averaged -$16.4 million across 5 years, with a median of -$5.6 million in 2024.
• The sharpest annual moves came in 2024 and 2026: EBT surged 211.96% in 2024, then tumbled 251.97% in 2026.
• Over 5 years, EBT stood at -$18.7 million in 2022, then jumped by 63.17% to -$6.9 million in 2023, then soared by 211.96% to $7.7 million in 2024, then plunged by 74.03% to $2.0 million in 2025, then plunged by 202.25% to -$2.0 million in 2026.
• According to Business Quant data, EBT over the past three periods registered -$2.0 million, -$4.8 million, and $2.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.